Require pharmaceutical companies to disclose the country of origin for all active ingredients in their medications.
One policy goal, tracked across every bill that has carried it.
What’s happening with Drug Origin Transparency Act of 2026?
The Drug Origin Transparency Act of 2026, known as H.R. 8339, has remained in the House Committee on Energy and Commerce since April 15, 2026. Members of this committee must take action for the bill to move forward, but most legislation fails to receive a committee vote. This lack of action is the standard outcome for the vast majority of bills introduced in Congress.
Updated July 9, 2026 · Generated by AI. Always verify with official sources.
Where it stands
Now carried by Drug Origin Transparency Act of 2026 (H.R. 8339 (119th)) →
Legislative Progress
Next up: A house committee · Nothing moves until they act.
How we got here
Every bill that has carried this goal, oldest first.
Died with Congress · Jan 3, 2025
Died when the 118th Congress ended without final passage. Bills must be reintroduced under a new number to be revived.
Reintroduced · Jan 3, 2025
Reintroduced from H.R. 3810 (118th), which died when its Congress ended.
H.R. 3810 (118th) →
Vehicles
Who’s behind it
Doris Matsui (D-CA)Wrote and sponsored the current bill.
